Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy

Launched by UNIVERSITY HOSPITAL, ANTWERP · Jul 29, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a specific heart condition called transthyretin amyloidosis cardiomyopathy (ATTR-CM) in patients who have idiopathic peripheral neuropathy, which means they are experiencing nerve problems for reasons that aren't fully understood. The goal of the study is to find out how often this heart condition occurs in these patients. By identifying ATTR-CM early, doctors hope to start treatment sooner, which could lead to better outcomes for patients.

To participate in this trial, you need to be an adult over 18 years old with a diagnosis of idiopathic peripheral neuropathy. However, patients with other known heart diseases or severe kidney issues are not eligible. The trial is not yet recruiting participants, but when it begins, those who qualify can expect thorough testing to help determine the presence of ATTR-CM. This could be an important step towards improving care for people with this often-overlooked condition.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • - Adult patients (\> 18 years old) with diagnosis of idiopathic peripheral neuropathy
• • Exclusion criteria
• • Patients with alternative established diagnosis of heart disease (ischemic heart disease, primary valvular heart disease, cardiomyopathies, pericardial disease)
• • Patients with end stage renal disease undergoing dialysis
• • Patients with other medical conditions recognized to impair the 1-year prognosis of patients